Are Unvaccinated Children and Adults a Threat to National Security? N o v 4 , 2 0 2 1 P r e s e n t e d t o : G r e g H u n t e r W a t c h D o g U S A P r e s e n t e d b y : K a r e n K i n g s t o n 2 Jan 20, 2020, based on CONFIRMED 2019 Novel Coronavirus cases, Sec. Azar determined 2019-nCoV, the virus that causes COVID-19 is a public health emergency that has significant potential to affect NATIONAL SECURITY https://www.phe.gov/emergency/news/healthactions/phe/Pages/2019-nCoV.aspx 3 2017 EUA ⎮ Guidance for Industry & Stakeholders Prepared By: HHS, FDA, OCET, CBER, CDREH, and CDER 1.. https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm#SexAndAge Today, July 3, 2021 Xavier Becerra, Secretary of HHS, continues to extend the EUA under the guise that COVID-19 is still a threat to national security. According to the VE and EUA Panel logic, those at the greatest risk to overwhelm our healthcare system only have a 5% chance of even contracting SARS-COV-2. As 80% of deaths occurred in adults aged 65 and older with 2 or more comorbidities, some were on hospice, had stage 4 cancer, Class IV congestive heart failure. June 24, 2021 >86% of adults aged 65 and older are vaccinated Between March of 2020 and June 23, 2021, a total of 324 young people (under age 18) died from deaths INVOLVING COVID-19 4 https://www.bmj.com/content /bmj/375/bmj.n2635.full.pdf 5 Pfizer Phase 3 Primary Efficacy Outcome was ONLY 7 DAYS Post 2-Dose (Data from Table 7) Efficacy of BNT162b2 Against CONFIRMED COVID-19 from 7 DAYS After Dose 2 in Participants with and without Evidence of Prior SARS-CoV-2 Infection, pg. 24 https://www.fda.gov/media/144416/download 6 Pfizer Phase 3 Primary Efficacy Outcome was ONLY 7 DAYS Post 2-Dose Study Group N-Value Number Infected (RT-PCR+) Infection Risk (IFR) Reduction in Infection Risk Vaccine Efficacy = Confidence Interval Placebo 18,559 169 .910% PFE Vaccine 18,708 9 .048% 0.862% 95% Total 37,307 (Data from Table 7) Efficacy of BNT162b2 Against CONFIRMED COVID-19 from 7 DAYS After Dose 2 in Participants with and without Evidence of Prior SARS-CoV-2 Infection, pg. 24 U.S. Phase 2/3 Trials were conducted in the US, Brazil, Argentina, S. Africa, Germany and Turkey US = 6,653 OUS = 36,998 % US = 6,653/43,651 = 15% of subjects were in the US CONCLUSION: The Pfizer BNT162b Reduces Risk of Infection by less than 1% for up to 7 DAYS Post 7-Days Second Dose Compared to Placebo. The Long-term Immunity Effect of BNT162b is Not Known, Nor Is the Reduction of Risk of Hospitalization or Death due to COVID-19. https://www.fda.gov/media/144416/download 7 Pfizer Phase 3 Primary Efficacy Outcome was ONLY 7 DAYS Post 2-Dose (Efficacy of BNT162b2 Against (Tested + “Not CONFIRMED”) COVID-19 from 7 DAYS After Dose 2 in Participants with and without Evidence of Prior SARS-CoV-2 Infection, pg. 41 https://www.fda.gov/media/144416/download 8 Why Weren’t ALL COVID-19 Outcomes Calculated in the Primary Endpoint? Unconfirmed COVID-19 Cases and Cases Past 7-Days 2 nd Dose Were not Counted Study Group N- Value Number Infected (Symptoms & RT-PCR+)) Infection Risk (IFR) Reduction in Infection Risk FAILED Vaccine Efficacy >30% Placebo 18,559 456 2.46% PFE Vaccine 18,708 418 2.23% 0.23% 9.34% = CI Total 37,307 Efficacy of BNT162b2 Against (Tested + Not Tested) COVID-19 from 7 DAYS After Dose 2 in Participants with and without Evidence of Prior SARS-CoV-2 Infection, pg. 41 WARNING: DATA WAS CHERRY-PICKED in PHASE 3 TRIALS. Approximately the SAME Number of Subjects Presented with COVID-19 Symptoms in Both Groups. Investigators Did Not Have Time to Test All Study Subjects. https://www.fda.gov/media/144416/download 9 FDA Efficacy Concerns Regarding Vaccine Efficacy https://www.fda.gov/media/144416/download N=153 10 10 https://www.fda.gov/media/151733/download Pfizer FDA Approval BLA Aug 23, 2021 11 1 Pfizer FDA BLA, Pg 25. Missing Information: Vaccine Effectiveness https://www.fda.gov/media/151733/download 12 https://go.boarddocs.com/ca/sandi/Board.nsf/files/C797R4004A4C/$file/Vaccine%20Mandate%2 12 13 https://cdn.pfizer.com/pfizercom/2020-11/C4591001_Clinical_Protocol_Nov2020.pdf 14 https://cdn.pfizer.com/pfizercom/2020-11/C4591001_Clinical_Protocol_Nov2020.pdf 15 https://www.fda.gov/media/143557/download?fbclid=IwAR1SooRjTDuhBPqM4TiD3O7vYgX4eAp3CCqB7SzCk04CMve_OzgtMNPfNkc FDA/CBER Plans for Monitoring COVID-19 Vaccine Safety & Effectiveness Presented by: Steve Anderson, PhD, MPP – Dir. Office of Biostats & Epidemiology, CBER October 22, 2020 – Vaccines & Related Biological Products Advisory Committee (VRBPAC)Meeting 16 Excerpt from my email sent to MSM, Congressmen and Influencers – May 26, 2021 https://www.hhs.gov/ohrp/sites/default/files/ohrp/policy/subjectwithdrawal.pdf “ A ttached please find , WO 2020/160397, the global patent for the mRNA lipid nanoparticle (LNP) vaccines granted by WIP O to Moderna on August 6, 2020. Please have an expert in auto-immune disease medical research review this patent and the ones linked in this email. I believe they will conclude that the COVID-19 injections are bioweapons that contain gain of function (GOF) chimeric viruses and toxins under the guise of mRNA therapeutic vaccines combined with a ‘diagnostic/therapeutic’ lipid nanoparticle (LNP) platform. Per the patent, the LNP can target specifics organs and systems throughout the body, including, but not limited to reproductive, cardiovascular, pulmonary, and the central nervous system, specifically crossing the blood brain barrier .”